June 2019 - Volume 3 - Issue - Contributor Index

Author:
Waage, A.

PROGNOSIS IN ELDERLY MULTIPLE MYELOMA PATIENTS IN THE HOVON-87/NMSG-18 STUDY BASED ON REVISED ISS AND SKY92-ISS: PS1374

Kuiper, R.; Broijl, A.; van Vliet, M. H.; More

HemaSphere. 3:628-629, June 2019.

CARFILZOMIB AND DEXAMETHASONE MAINTENANCE PROLONG TIME TO PROGRESSION: S1602: FOLLOWING SALVAGE ASCT IN MULTIPLE MYELOMA: A RANDOMIZED PHASE 2 TRIAL BY THE NORDIC MYELOMA STUDY GROUP

Gregersen, H.; Peceliunas, V.; Remes, K.; More

HemaSphere. 3:737-738, June 2019.

Author:
Wach, M.
Author:
Wada, C.
Author:
Wada, H.

EVALUATION OF THE IMMUNITY TO MEASLES, MUMPS AND RUBELLA IN ADULT PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: PS1277

Kawamura, K.; Nakasone, H.; Wada, H.; More

HemaSphere. 3:584-585, June 2019.

SAFETY AND EFFICACY OF LIVE ATTENUATED VARICELLA VACCINE FOR PREVENTING VARICELLA ZOSTER VIRUS DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-CENTER STUDY: S1639

Kawamura, K.; Nakasone, H.; Akahoshi, Y.; More

HemaSphere. 3:758, June 2019.

Author:
Wadleigh, M.

A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM-151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB: S828

Verstovsek, S.; Talpaz, M.; Wadleigh, M.; More

HemaSphere. 3:367, June 2019.

Author:
Wagenführ, L.

CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA: S1614

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3:744-745, June 2019.

Author:
Wagner, C.
Author:
Wagner, E.
Author:
Wagner, F.
Author:
Wagner, K.
Author:
Wagner, L.

TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY: PS1384

Jagannath, S.; Narang, M.; Ailawadhi, S.; More

HemaSphere. 3:634, June 2019.

ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY: PS1075

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3:487, June 2019.

Author:
Wahida, A.
Author:
Wahlgren, M.
Author:
Wahlin, B.

ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY: PF311

Majidi, F.; Martino, S.; Kondakci, M.; More

HemaSphere. 3:108, June 2019.

Author:
Wais, V.
Author:
Wajant, H.

HACE1, A NOVEL TUMOR SUPPRESSOR GENE WHICH REGULATE THE RESPONSE OF VENETOCLAX, GANT61 AND NECROPTOSIS ACTIVATORS BY CONTROLLING C-FLIP, GLI2 AND BCL2 GENES IN ACUTE MYELOID LEUKEMIA: PS1001

Garitano, A.; Teufel, E.; Kreckel, J.; More

HemaSphere. 3:450, June 2019.

Author:
Wakabayashi, M.

LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA: PS1259

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3:575-576, June 2019.

Author:
Wakeman, S.

MULTICENTRE STANDARDIZATION OF MINIMAL RESIDUAL DISEASE DETECTION AND QUANTITATION USING THE EUROCLONALITY-NGS ASSAY: PF175

Svaton, M.; Fronkova, E.; Kotrova, M.; More

HemaSphere. 3:39-40, June 2019.

Author:
Wakita, K.
Author:
Walbaum, C.
Author:
Walewski, J.

FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY: S820

Gallamini, A.; Straus, D.; Dlugosz-Danecka, M.; More

HemaSphere. 3:362-363, June 2019.

Author:
Wali, Y.
Author:
Walker, B.
Author:
Walker, J. S.
Author:
Walker, P.

ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY: PS1075

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3:487, June 2019.

Author:
Wall, D.
Author:
Wall, K.
Author:
Wall, M.

CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA: S1614

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3:744-745, June 2019.

Author:
Wallace, P.
Author:
Waller, C.

RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA: RESULTS FROM THE MPNSG-0212 COMBINATION TRIAL (NCT01644110): S1608

Stegelmann, F.; Koschmieder, S.; Isfort, S.; More

HemaSphere. 3:740-741, June 2019.

Author:
Waller, J.

IMPACT OF SICKLE CELL DISEASE FROM PATIENTS' AND PHYSICIANS' PERSPECTIVES: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY): PB2300

Osunkwo, I.; Abboud, M.; Andemariam, B.; More

HemaSphere. 3:1026-1027, June 2019.

Author:
Walter, C.
Author:
Walter, R.
Author:
Walter, R. B.

SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS: PF253

Howard, N. P.; Halpern, A. B.; Othus, M.; More

HemaSphere. 3:78, June 2019.

Author:
Walter, W.
Author:
Walters, M.
Author:
Walters, M. C.

CLINICAL OUTCOMES OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT β-THALASSAEMIA (TDT) FOLLOWING COMPLETION OF THE NORTHSTAR (HGB-204) STUDY: S141

Walters, M. C.; Kwiatkowski, J. L.; Rasko, J. E.J.; More

HemaSphere. 3:22, June 2019.

UPDATED RESULTS FROM THE HGB-206 STUDY IN PATIENTS WITH SEVERE SICKLE CELL DISEASE TREATED UNDER A REVISED PROTOCOL WITH LENTIGLOBIN GENE THERAPY USING PLERIXAFOR-MOBILISED HAEMATOPOIETIC STEM CELLS: S1633

Kanter, J.; Thompson, A. A.; Mapara, M. Y.; More

HemaSphere. 3:754-755, June 2019.

Author:
Walzer, T.
Author:
Wan, D.
Author:
Wan, Y.

TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS): S837

Fenaux, P.; Steensma, D. P.; Van Eygen, K.; More

HemaSphere. 3:372-373, June 2019.

Author:
Wandroo, F.

REAL WORLD TYROSINE KINASE INHIBITOR TREATMENT PATHWAYS, MONITORING PATTERNS AND RESPONSES COMPARED WITH ELN RECOMMENDATIONS IN CHRONIC MYELOID LEUKAEMIA: FINAL ANALYSIS OF THE UK TARGET CML STUDY: PS1182

Milojkovic, D.; Cross, N. C.; Ali, S.; More

HemaSphere. 3:538-539, June 2019.

Author:
Wang, A.
Author:
Wang, A. K.

LONG-TERM EFFICACY AND SAFETY OF INOTERSEN FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: NEURO-TTR OPEN-LABEL EXTENSION 2-YEAR UPDATE: PS1221

Brannagan, T.; Cruz, Waddington M.; Wang, A. K.; More

HemaSphere. 3:557, June 2019.

Author:
Wang, B.

LONG-TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM-6, A REAL-WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA): PF729

Rifkin, R. M.; Yimer, H. A.; Noga, S. J.; More

HemaSphere. 3:319, June 2019.

Author:
Wang, C.

MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP-FRACTIONATED DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL): PS1094

Yoon, S.-S.; Matasar, M.; Sehn, L. H.; More

HemaSphere. 3:496, June 2019.

Author:
Wang, C.-C.

INCIDENCE, CLINICAL FEATURES, RISK FACTORS AND OUTCOMES OF REFRACTORY ACQUIRED IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: A CHINESE MULTI-CENTER EXPERIENCE: PF805

Gui, R.-Y.; Zhang, G.-C.; Wang, C.-C.; More

HemaSphere. 3:355, June 2019.

Author:
Wang, D.

ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY: PS1075

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3:487, June 2019.

Author:
Wang, E.

RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS: PF668

Pemmaraju, N.; Ali, H.; Gupta, V.; More

HemaSphere. 3:286-287, June 2019.

RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): PF672

Patnaik, M.; Ali, H.; Gupta, V.; More

HemaSphere. 3:289, June 2019.

RESULTS OF PIVOTAL PHASE 2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN): PS1063

Pemmaraju, N.; Lane, A.; Sweet, K.; More

HemaSphere. 3:481, June 2019.

OPEN-LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3-MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT: PS1065

Esteve, J.; Schots, R.; Del Castillo, Bernal T.; More

HemaSphere. 3:482, June 2019.

Author:
Wang, E. S.

FT-2102, AN IDH1 M INHIBITOR, COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS): RESULTS FROM A PHASE 1 STUDY: PF269

Cortes, J. E.; Watts, J.; Baer, M.; More

HemaSphere. 3:86-87, June 2019.

GLASDEGIB WITH LDAC IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: EFFECTS ON TRANSFUSIONS AND MARROW RECOVERY VS LDAC ALONE: PF272

Wang, E. S.; Heuser, M.; Montesinos, P.; More

HemaSphere. 3:87, June 2019.

Author:
Wang, F.

RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY: PF205

Abbas, H.; Alfayez, M.; Wang, F.; More

HemaSphere. 3:54-55, June 2019.

THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML: S833

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3:370, June 2019.

Author:
Wang, H.

IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT NEWLY-DIAGNOSED AML: UPDATED RESULTS FROM A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY: PS1025

Roboz, G. J.; DiNardo, C. D.; Stein, E. M.; More

HemaSphere. 3:461-462, June 2019.

IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY: PS1337

Foran, J. M.; DiNardo, C. D.; Watts, J. M.; More

HemaSphere. 3:610-611, June 2019.

Show: